========== 1_pe_ctpa_negative_anticoag_keyed ==========
Safety: unsafe | Accuracy: unsafe_or_inaccurate | OBA: poor | Faculty: yes
Summary: The keyed answer is unsafe as it recommends anticoagulation for PE despite a negative CTPA, contradicting the definitive investigation result. This creates a significant clinical error and fairness issue.
High priority: The keyed answer suggests starting therapeutic-dose rivaroxaban for pulmonary embolism despite a negative CTPA, which is clinically incorrect and unsafe.
PASS

========== 2_pe_rivaroxaban_pt_inr_monitoring ==========
Safety: unsafe | Accuracy: unsafe_or_inaccurate | OBA: poor | Faculty: yes
Summary: The keyed answer is clinically incorrect as PT and INR monitoring is not required for rivaroxaban. The appropriate monitoring involves renal function, liver function, FBC, and assessing bleeding risk and adherence. This item is unsafe and requires correction.
High priority: The keyed answer is incorrect. PT and INR monitoring is not required for patients on rivaroxaban. Instead, monitoring should focus on renal function, liver function, FBC, bleeding risk, and adherence.
PASS

========== 3_pe_diagnosis_sound ==========
Safety: no_major_concerns | Accuracy: good | OBA: good | Faculty: no
Summary: The keyed answer of pulmonary embolism is clinically correct given the high Wells score and positive CTPA findings. There are no major safety or fairness issues with the question.
PASS

========== 4_acs_interpretation_sound ==========
Safety: no_major_concerns | Accuracy: good | OBA: good | Faculty: no
Summary: The keyed answer of ST-elevation myocardial infarction is clinically sound given the presentation of ST elevation and rising troponin levels. There are no major safety or fairness issues with the question.
PASS

========== SUMMARY ==========
Passed: 4 Failed: 0